Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNET5 medulloblastoma trial in children older than 3 to 5 years and registry for genetic predisposition
2011-004868-30Phase 2Active
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Nov 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cisplatin, carboplatin, lomustine, vincristine, cyclophosphamide and 3 more in medulloblastoma (4 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoints: Event-free survival and 3-year event-free survival rate. Started Nov 2011; status: active.
02
Drugs
cisplatincarboplatinlomustinevincristinecyclophosphamide
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on 2011-004868-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004868-30.